Gene Therapy for Dry Mouth

Enrolling by invitation at 7 trial locations

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: MeiraGTx, LLC

Disqualifiers: Withdrew consent, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 3 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

Duration: 12 months

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial evaluates a new gene therapy treatment, AAV2-hAQP1, to determine its safety and effectiveness for individuals with dry mouth caused by radiation therapy. It targets those experiencing significant, lasting dry mouth after cancer treatments. The trial includes two main groups: one continues with long-term follow-up, while the other transitions from a placebo to the active treatment. Individuals who participated in a previous study with this treatment and did not withdraw consent are eligible to join. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications.

Is there any evidence suggesting that AAV2-hAQP1 is likely to be safe for humans?

Research has shown that a specific gene therapy, AAV2-hAQP1, appears safe in animal studies, which did not find any significant harmful effects after treatment. In clinical trials, this therapy aims to help people with radiation-induced dry mouth regain salivary flow. So far, results look promising, with no major safety issues reported. Researchers continue to study this treatment to confirm its safety and effectiveness in humans. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising?

Researchers are excited about AAV2-hAQP1 for treating dry mouth because it uses a novel approach: gene therapy. Unlike typical treatments like saliva substitutes or medications that stimulate saliva production, AAV2-hAQP1 delivers a gene directly into the cells of the salivary glands to increase the production of aquaporin-1, a protein that facilitates water transport, potentially restoring natural saliva flow. This targeted delivery could offer a more permanent solution by addressing the root cause of dry mouth rather than just alleviating symptoms. This innovative mechanism makes AAV2-hAQP1 a promising candidate for providing long-term relief for patients suffering from dry mouth.

What evidence suggests that AAV2-hAQP1 might be an effective treatment for radiation-induced xerostomia?

Research shows that a new gene therapy, AAV2-hAQP1, may help treat radiation-induced dry mouth. Studies on small pigs have demonstrated that this treatment can restore saliva production in damaged salivary glands without causing harm. In humans, early results suggest that adding the hAQP1 gene can increase saliva production and alleviate dry mouth symptoms. Clinical data indicate that patients report significant improvements, such as more saliva and reduced dry mouth discomfort. In this trial, participants in the active treatment group will receive AAV2-hAQP1, while those in the follow-up group will continue to be monitored. Overall, these findings offer hopeful evidence that AAV2-hAQP1 could be effective for people with radiation-induced dry mouth. ^{1 3 4 6 7}

Are You a Good Fit for This Trial?

This trial is for adults with moderate to severe dry mouth (Grade 2 or Grade 3) caused by radiation therapy. Specific eligibility details are not provided, but typically participants must meet certain health standards and may be excluded based on factors that could impact the study's results.

Inclusion Criteria

Received study drug in Study MGT-AQP1-201

Exclusion Criteria

Withdrew consent to participate in Study MGT-AQP1-201.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

Treatment

Participants receive AAV2-hAQP1 gene therapy or transition from placebo to active treatment

12 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

48-60 months

What Are the Treatments Tested in This Trial?

Interventions

• AAV2-hAQP1

Trial Overview

The trial is testing a gene therapy called AAV2-hAQP1, which is administered into both parotid salivary glands. The goal is to evaluate the long-term safety and effectiveness of this treatment in reducing symptoms of dry mouth following radiation.

How Is the Trial Designed?

Group I: Active treatment group Experimental Treatment 1 Intervention

Participants who were randomized to placebo treatment in Study MGT-AQP1-201, will be offered to transition from the long-term follow-up schedule to an active treatment schedule at the time of unblinding. Study drug administration should be completed after unblinding and after confirmation of the participant's continued eligibility for treatment. Upon completion of the 12-month primary treatment period, participants will continue in the study according to a follow-up schedule, to complete a total of 60 months of follow-up after AAV2-hAQP1 administration.

Group II: Follow-up group Active Control 1 Intervention

Participants who were randomized to AAV2-hAQP1 treatment in Study MGT-AQP1-201 will continue in this long-term follow-up schedule to complete an additional 48 months of follow-up after their end-of-study visit in Study MGT-AQP1-201. All study participants are to be followed for a period of 60 months after vector administration.

AAV2-hAQP1 is already approved in United States, Canada, United Kingdom for the following indications:

Approved in United States as AAV2-hAQP1 for:

• Radiation-induced late xerostomia (Grade 2/3)

Approved in Canada as AAV2-hAQP1 for:

• Radiation-induced late xerostomia (Grade 2/3)

Approved in United Kingdom as AAV2-hAQP1 for:

• Radiation-induced late xerostomia (Grade 2/3)

Who Is Running the Clinical Trial?

MeiraGTx, LLC

Lead Sponsor

Trials

6

Recruited

310+

Published Research Related to This Trial

A single dose of AAV2hAQP1 delivered to irradiated parotid glands in minipigs significantly increased salivary flow to about 35% of pre-irradiation levels, demonstrating its efficacy in treating salivary hypofunction.

The treatment was safe, with minimal changes in clinical chemistry and hematology, and it effectively targeted duct cells, suggesting potential for extended relief in patients with similar radiation-induced salivary issues.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

AAV2-mediated transfer of the human aquaporin-1 cDNA restores fluid secretion from irradiated miniature pig parotid glands. Gao, R., Yan, X., Zheng, C., et al.[2021]

The recombinant adenovirus AdhAQP1 effectively increased the expression of human aquaporin-1 in epithelial cells, leading to a fourfold increase in fluid movement across cell monolayers compared to controls.

In a rat model, administering AdhAQP1 to submandibular glands after radiation treatment resulted in a two- to threefold increase in salivary secretion, suggesting its potential as a treatment for postradiation salivary hypofunction.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Increased fluid secretion after adenoviral-mediated transfer of the aquaporin-1 cDNA to irradiated rat salivary glands. Delporte, C., O'Connell, BC., He, X., et al.[2023]

In a clinical trial involving five subjects, administration of the AdhAQP1 gene therapy for radiation-induced salivary hypofunction resulted in significant long-term increases in parotid salivary flow (71-500% above baseline) lasting 3-4.7 years after treatment.

There were no clinically significant adverse events reported, indicating that AdhAQP1 is a safe intervention, and the benefits of the treatment persisted much longer than typically expected from first-generation adenoviral vectors.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Late responses to adenoviral-mediated transfer of the aquaporin-1 gene for radiation-induced salivary hypofunction. Alevizos, I., Zheng, C., Cotrim, AP., et al.[2019]

A 13-week safety study in Balb/c mice showed that the recombinant adeno-associated vector (rAAV2hAQP1) used to treat radiation-induced salivary gland damage was clinically safe, with no significant adverse effects observed in body weight, food or water consumption, and clinical chemistry evaluations.

The treatment resulted in only mild inflammation at the injection site and localized vector distribution, with no significant changes in liver, kidney, or cardiac function, indicating a favorable safety profile for future clinical trials.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Toxicity and biodistribution of the serotype 2 recombinant adeno-associated viral vector, encoding Aquaporin-1, after retroductal delivery to a single mouse parotid gland. Momot, D., Zheng, C., Yin, H., et al.[2021]

In a Phase I clinical trial involving a patient with radiation-induced salivary hypofunction, the administration of an adenoviral vector (AdhAQP1) successfully delivered the human aquaporin-1 gene, with detectable levels in parotid saliva one week post-treatment.

The patient remained asymptomatic throughout the study, and no infectious virus or vector was found in serum or subsequent saliva samples, suggesting that the treatment was safe and did not lead to adverse effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Transient detection of E1-containing adenovirus in saliva after the delivery of a first-generation adenoviral vector to human parotid gland. Zheng, C., Nikolov, NP., Alevizos, I., et al.[2021]

In a clinical trial involving 11 subjects, the adenoviral vector AdhAQP1 significantly improved saliva flow rates and reduced symptoms in patients with radiation-damaged parotid glands, with effects lasting longer than expected (7-42 days).

The study suggests that the human cytomegalovirus promoter/enhancer (hCMVp) in AdhAQP1 remains unmethylated in human salivary gland cells, allowing for prolonged expression and function of the human aquaporin-1 protein, unlike in rodent models where methylation led to decreased expression.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Persistence of hAQP1 expression in human salivary gland cells following AdhAQP1 transduction is associated with a lack of methylation of hCMV promoter. Zheng, C., Baum, BJ., Liu, X., et al.[2019]

Citations

1.

clinicaltrials.gov

clinicaltrials.gov/study/NCT02446249

Safety of a Single Administration of AAV2hAQP1, an Adeno ...

Minipig studies have shown that the AAV2hAQP1 strategy for restoring salivary flow to IR-damaged salivary glands is effective without untoward effects after ...

2.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC2818419/

Development of a gene transfer-based treatment for ...

Thus, this study also is testing an important proof of concept: does hAQP1 gene transfer increase salivary flow and improve dry mouth in humans with RT-induced ...

3.

pnas.org

pnas.org/doi/10.1073/pnas.1210662109

Early responses to adenoviral-mediated transfer of the ...

We conducted a phase I clinical trial to test the safety and biologic efficacy of serotype 5, adenoviral-mediated aquaporin-1 cDNA transfer to a single ...

4.

investors.meiragtx.com

investors.meiragtx.com/news-releases/news-release-details/meiragtx-announces-positive-clinical-data-aquax-phase-1-0

MeiraGTx Announces Positive Clinical Data from the AQUAx ...

The data demonstrate clinically important improvements in two different patient reported outcome questionnaires for xerostomia, as well as meaningful increases ...

5.

withpower.com

withpower.com/trial/phase-2-xerostomia-7-2024-4adf1

Gene Therapy for Dry Mouth · Info for Participants

Research shows that AAV2-hAQP1 can increase saliva production in animals with damaged salivary glands, and similar treatments have helped improve saliva flow in ...

6.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC3015016/

AAV2-mediated transfer of the human aquaporin-1 cDNA ...

The findings demonstrate that localized delivery of AAV2hAQP1 to IR-damaged parotid glands leads to increased fluid secretion from surviving duct cells.

7.

clinicaltrial.be

clinicaltrial.be/en/details/74127?per_page=20&only_recruiting=0&only_eligible=0&only_active=0

Safety of a Single Administration of AAV2hAQP1, an Adeno ...

Minipig studies have shown that the AAV2hAQP1 strategy for restoring salivary flow to IR-damaged salivary glands is effective without untoward effects after ...